Femara Tablets 2.5Mg (3 Strip = 30 Tablets)

Trusted Estrogen Suppression for Postmenopausal Breast Cancer Management

Femara Tablets 2.5mg are a clinically proven hormonal therapy designed for the treatment of hormone-dependent breast cancer in postmenopausal women. Containing the active ingredient letrozole, Femara works by significantly reducing estrogen levels in the body, a key driver of tumor growth in estrogen receptor–positive breast cancer.

Prescribed by oncology specialists worldwide, Femara plays a vital role in both early and advanced stages of breast cancer treatment, offering patients an effective, targeted approach to long-term disease control.

How Femara Works

Letrozole is a nonsteroidal aromatase inhibitor that blocks the aromatase enzyme responsible for converting androgens into estrogens. In postmenopausal women, estrogen is mainly produced through this conversion rather than ovarian activity.

By inhibiting estrogen synthesis, Femara helps shrink estrogen-dependent tumors, slow disease progression, and reduce the risk of recurrence—without significantly interfering with adrenal hormone production.

Comprehensive Treatment Across Cancer Stages

Femara Tablets are indicated for a wide range of breast cancer treatment scenarios. They are used as a first-line treatment for advanced hormone-dependent breast cancer, as well as an adjuvant therapy following surgery in early-stage disease.

Femara is also prescribed as an extended adjuvant treatment after five years of tamoxifen therapy, offering continued protection against recurrence. In selected cases, it may be used as neoadjuvant therapy to reduce tumor size when surgery or chemotherapy is not immediately appropriate.

Benefits of Femara Tablets 2.5mg

Femara provides consistent estrogen suppression that supports effective tumor regression and long-term cancer management. It helps delay disease progression, reduces recurrence risk, and allows many patients to maintain quality of life during treatment.

The once-daily oral tablet ensures convenience and compliance, making it suitable for extended treatment durations as recommended by healthcare professionals.

Safety, Monitoring, and Precautions

Femara should only be used under medical supervision. As estrogen plays a role in bone health, patients may experience a reduction in bone mineral density during therapy. Regular bone density assessments and cholesterol monitoring are recommended, especially in patients with osteoporosis risk factors.

Caution is advised for patients with hepatic or renal impairment, and dose adjustments may be necessary. Femara is contraindicated during pregnancy and breastfeeding due to the risk of fetal harm.

Side Effects Overview

Common side effects may include hot flushes, fatigue, joint pain, nausea, and changes in bone density. Less common but serious effects such as thromboembolic events or liver complications require immediate medical attention.

Patients should report any unusual symptoms to their healthcare provider promptly.

Call to Action

If you or a loved one requires effective hormonal therapy for estrogen-dependent breast cancer, Femara Tablets 2.5mg offer a trusted and clinically validated treatment option. Always use under the guidance of an oncology specialist and take the next step toward confident, evidence-based cancer care by consulting your healthcare provider today.